Merck hopes COVID drug approved before 2021 ends

Thursday, 30. September 2021 13:42

Merck & Co. Inc. President and CEO Robert Davis said on Thursday that he hopes that his company's experimental coronavirus pill molnupiravir would receive an emergency use authorization (EUA) in the United States before the end of the year.

"The primary completion date for our studies is the beginning of November," he revealed in a CNBC interview, adding that "the enrollment for that study continues to go quite well."

The company is "excited to hopefully" introduce another weapon to fight the pandemic on a global level, Davis pointed out.

Related Links: Merck & Co. Inc.
Author:
Breaking the News / MS